Skip to content

Source filing unavailable

Q4 2014 · —
Revenue$328.14M+39.2% vs Q4 2013+7.0% vs Q3 2014
Net Income$81.61M+47.6% vs Q4 2013+216.7% vs Q3 2014
EPS Diluted$1.30+44.4% vs Q4 2013+217.1% vs Q3 2014
Gross Profit$295,415,000+41.9%
Operating Incomederived$129,919,000+37.5%
Operating Cash Flowderived$134,262,000+69.9%
Free Cash Flowderived$120,714,000+59.0%
Margins · derived
Gross margin90.0%+1.7 pt vs Q4 2013
Operating margin39.6%−0.5 pt vs Q4 2013
Net margin24.9%+1.4 pt vs Q4 2013

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ4 2014Q4 2013Q4 2012Q4 2011
Revenue$328.14M$235.77M$183.70M$83.54M
Net Income$81.61M$55.29M$200.55M$37.47M
EPS Diluted$1.30$0.90$3.28$0.79

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR